Literature DB >> 29434384

Formulary Drug Review: Betrixaban.

Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Entities:  

Keywords:  anticoagulants; critical care; formulary management/P&T

Year:  2017        PMID： 29434384      PMCID： PMC5805016          DOI： 10.1177/0018578717739397

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  11 in total

1.  The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.

Authors:  C Michael Gibson; Rim Halaby; Serge Korjian; Yazan Daaboul; Douglas F Arbetter; Megan K Yee; Samuel Z Goldhaber; Russel Hull; Adrian F Hernandez; Shiao-Ping Lu; Olga Bandman; Janet M Leeds; Alex Gold; Robert A Harrington; Alexander T Cohen
Journal:  Am Heart J       Date:  2016-12-18       Impact factor: 4.749

Review 2.  Reversal of anticoagulants: an overview of current developments.

Authors:  Andreas Greinacher; Thomas Thiele; Kathleen Selleng
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

3.  Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).

Authors:  C Michael Gibson; Gerald Chi; Rim Halaby; Serge Korjian; Yazan Daaboul; Purva Jain; Douglas Arbetter; Samuel Z Goldhaber; Russel Hull; Adrian F Hernandez; Alex Gold; Olga Bandman; Robert A Harrington; Alexander T Cohen
Journal:  Circulation       Date:  2016-11-14       Impact factor: 29.690

Review 4.  Monitoring plasma levels of factor Xa inhibitors: how, why and when?

Authors:  Meyer-Michel Samama; Jean Amiral; Céline Guinet; Léna Le Flem; Jerard Seghatchian
Journal:  Expert Rev Hematol       Date:  2013-04       Impact factor: 2.929

5.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

6.  Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.

Authors:  Weili Feng; Kezhou Wu; Zhaoyong Liu; Gengbin Kong; Zhihua Deng; Shubiao Chen; Yudan Wu; Mengmeng Chen; Shuo Liu; Hu Wang
Journal:  Thromb Res       Date:  2015-10-20       Impact factor: 3.944

7.  The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.

Authors:  Alexander T Cohen; Robert Harrington; Samuel Z Goldhaber; Russell Hull; C Michael Gibson; Adrian F Hernandez; Michael M Kitt; Todd J Lorenz
Journal:  Am Heart J       Date:  2013-12-10       Impact factor: 4.749

Review 8.  Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.

Authors:  Noel C Chan; Vinai Bhagirath; John W Eikelboom
Journal:  Vasc Health Risk Manag       Date:  2015-06-26

9.  Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.

Authors:  C Michael Gibson; Serge Korjian; Gerald Chi; Yazan Daaboul; Purva Jain; Douglas Arbetter; Samuel Z Goldhaber; Russel Hull; Adrian F Hernandez; Renato D Lopes; Alex Gold; Alexander T Cohen; Robert A Harrington
Journal:  J Am Heart Assoc       Date:  2017-07-11       Impact factor: 5.501

10.  Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Authors:  Alexander T Cohen; Robert A Harrington; Samuel Z Goldhaber; Russell D Hull; Brian L Wiens; Alex Gold; Adrian F Hernandez; C Michael Gibson
Journal:  N Engl J Med       Date:  2016-05-27       Impact factor: 91.245
View more
  1 in total

Review 1.  Drug-Drug Interactions with Direct Oral Anticoagulants.

Authors:  Kathrin I Foerster; Simon Hermann; Gerd Mikus; Walter E Haefeli
Journal:  Clin Pharmacokinet       Date:  2020-08       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.